期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

早期非小细胞肺癌大分割放射治疗临床研究 被引量：4

Clinical Research of Hypofractionated Radiotherapy for Early-stage Non-Small-Cell Lung Cancer
下载PDF
导出
摘要 目的:探讨三维适形放疗(3-dimensional conformal radiotherapy,3D-CRT)大分割放射治疗早期非小细胞肺癌的疗效和毒性反应。方法:11例早期非小细胞肺癌(I期8例,IIB期3例;中位年龄72岁)三维适形大分割放射治疗(hypofractionation radiotherapy,HORT)全程或后程推量,肿瘤剂量60Gy^76Gy,3Gy^8Gy/次,1次/天,3次~5次/周。生物等效剂量76.8Gy^105.6 Gy。中位随访时间54个月。根据WHO标准评价近期疗效,RTOG标准评价毒性反应。结果:完全缓解(CR)9.09%(1/11),部分缓解(PR)81.8%(9/11),稳定(NC)9.09%(1/11)。中位生存时间39个月。1,3及5年总生存率分别为81.8%,58.4%和18%,1,3及5年肿瘤相关生存率分别为91%,91%和18%。放射性食管炎27.3%(2级2例,3级1例),急性放射性肺炎(2级1例)9.09%。结论:三维适形大分割放射治疗早期非小细胞肺癌近期疗效和生存率优于常规分割放疗,放疗毒性未见明显增加,耐受性好,是一种有效安全的局部治疗手段。 Objective： To evaluate the effect and toxicity of HORT for early-stage NSCLC. Methods： 11 patients （Medi- urn age 72 years,8 stage 1,3 stage IIB） with early-stage non-small-cell lung cancer were treated by HORT. A total dose of 60-76Gy,3- 8Gy/f/d,3-Sf/wwas received. Results： The response rate （CR＋PR） wasg0.9%, including （CR） 9.09% （1/11） and （PR） 81.8 % （9/11）. The medium survival time was 39 monthes. The 1,3,5y overall survival rate （OSR） were 81.8%, 58.4%, and 18% respectively. And the 1,3,5y disease-specific survival rate（DSS） were 91% ,91%, and 18% respectively. Conclusion： The HORT for early-stage NSCLC had satisfying response. The radiation toxicity of HORT was tolerable. HORT is one of safe and effective local treatments.
作者 刘子莹 卢冰 欧阳伟炜 甘家应 姜彬
机构地区 贵州省肿瘤医院胸部肿瘤科
出处 《肿瘤预防与治疗》 2008年第2期152-154,235,共4页 Journal of Cancer Control And Treatment
关键词 非小细胞肺癌 三维适形放疗 大分割放疗 生存率 毒性反应 NSCLC 3-DCRT Hypofractionated Radiotherapy Overall Survival Rate Radiation Toxicity.
分类号 R734.2 [医药卫生—肿瘤] R730.55 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1[1]Mountain CF.Revision in the international system for staging lung cancer[J].Chest,1997,111:1710-1717.
  • 2[2]Jeremic B,Shibamoto Y,Acimovic L,et al.Hyperfractionated radiotherapy for clinical stage Ⅱ non-small cell lung cancer[J].Radiother Oncol,1999,51(2):141-145.
  • 3[3]Cheung PCF,Markillop WJ,Dixon P,et al.Involved-field radiotherapy alone for early-stage non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2000,48:703-710.
  • 4[5]Morita K,Fuwa N,Suzuki Y,et al.Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I:A retrospective analysis of 149 patients[J].Radiother Oncol,1997,42:31-36.
  • 5吕纪马,王绿化,周宗玫,张红星,陈东福.放射治疗同步紫杉醇化疗局部晚期非小细胞肺癌的Ⅱ期临床研究[J].中华放射肿瘤学杂志,2004,13(2):89-92. 被引量：68
  • 6[7]Martel MK,Ten-Haken RK,Hazuka MB,et al.Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients[J].Lung Cancer,1999,24:31-37.
  • 7[8]Perez VA,Pajak TF,RubinP,et al.Long-temobservations of the pattems of failure in patients with unresectable non-small cell lung cancer treated with definitive radiotherapy[J].Cancer,1987,59(2):1874-1881.
  • 8[9]Kong FM,Ten Haken RK,Schipper MJ,et al.High-dose radiation improed local tumor control and survival in patients with inoperable/unresectable non-small-cell lung cancer:long-term result of a radiation dose escalation study[J].Int J Radiat Oncol Biol Phys,2005,63(2):324-333.
  • 9[10]L.Christine Fang,Ritsuko Komaki,Pamela Allen,et,al.Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional VS.three-dimensional radiotherapy[J].Int J Radiation Oncology Biol Phys,2006,66(1):108-116.
  • 10[11]Onishi H,Komiyama K,Komiyama T,et al.Clinical outcome of stereotactic radiofherapy for stage I non-small cell lung cancer using a novel irradiation technique:patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner[J].Lung Cancer,2004,45:45-55.

二级参考文献26

  • 1Zanelli GD,Quaia M,Robieux I,et al. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and phamacokinetic calculations. Eur J Cancer, 1997, 33:486-492.
  • 2Tishler RB, Schiff PB, Geard CR , et al . Taxol: a novel radiation sensitiser. Int J Radiat Oncol Biol Phys , 1992,22:613-617.
  • 3Liebmann J, Cook JA, Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Nantl Cancer Inst , 1999,86:441-446.
  • 4Geard CR, Jones JM , Shiff PB. Taxol and radiation. J Nantl Cancer Inst Monogr , 1993,15:89-94.
  • 5Reckzeh B, Merte H, Pfluger H, et al . Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-snal cell lung cancer. J Clin Oncol , 1996, 14:1071-1076.
  • 6Choy H, Akerley W, Safran H, et al. Phrase I trail of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol , 1994, 12:2682-2686.
  • 7Choy H, Safran H, Akerley W, et al. Phase Ⅱ trail of weekly paclitaxel and concurren! radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res, 1998, 412:1931-1936.
  • 8Kirkbride P, Gelmon K, Eisenhauer E, et al. Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin Radiat Oncol, 1999,9 Suppl 1:102-107.
  • 9Wolf M, Faoro C, Goerg C, et al. Paclitaxel and smmutaneous radiation in the treatment of stage Ⅲ A/B non-small cell lung cancer . Semin Oncol,1996, 23(6 Suppl 16): 108-112.
  • 10Lau DHM, Ryu JK, Gandara DR, et al. Twice-weekly pac litaxel and radiation for stage Ⅲ non-small cell lung cancer. Semin Oncol , 1997,24(4 Suppl 12) : 106-109.

共引文献95

同被引文献43

引证文献4

二级引证文献7

肿瘤预防与治疗
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部